Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis

Figure 1

Association with LYNX1 expression and clinicopathological characteristics including (a) clinical stage, primary therapy outcome (b), cancer status (c), histologic grade (d), tumor residual disease (e), and anatomic neoplasm subdivision (f) in patients with ovarian serous cystadenocarcinoma (OVs) in The Cancer Genome Atlas (TCGA) cohort.

(a)

(b)

(c)

(d)

(e)

(f)